Neuronetics, Inc. announced that they have received 510(k) clearance for their obsessive-compulsive disorder (OCD) Motor Threshold (MT) Cap technology for NeuroStar® Advanced Therapy for Mental Health. Determining a patient's Motor Threshold (MT) is a critical step to establish the patient's prescription prior to starting treatment. NeuroStar stands out as the only TMS system with FDA clearance for MT Caps designed for both OCD and major depressive disorder (MDD).
The MT Cap simplifies the initial NeuroStar coil placement by providing a consistent starting location and a step-by-step process to map a patient's motor cortex, effectively shortening the time and reducing the number of steps involved. The OCD MT Cap shares the same advantages as the current MDD MT Cap. This includes its compatibility with Fast MT, providing up to a 40% time savings for clinicians and patients during the initial visit.